文献速递膀胱癌与上尿路尿路上皮癌

开放根治性膀胱切除术与机器人辅助根治性膀胱切除术联合体内尿流改道:单中心随机对照试验的早期结局

Open Radical Cystectomy versus Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Early Outcomes of a Single-Center Randomized Controlled Trial.
PubMed 文献 · J Urol · 2022-02-02

单中心随机对照试验纳入116例(RARC 58例、ORC 58例)膀胱癌患者,比较机器人辅助根治性膀胱切除术联合完全体内尿流改道与开放根治性膀胱切除术的围手术期及6个月结局。主要终点围手术期总体输血率RARC组22%显著低于ORC组41%(p=0.046),但围手术期并发症、住院时间和6个月健康相关生活质量两组基本相当。

要点

  • RARC联合体内尿流改道组围手术期总体输血率22%,显著低于ORC组的41%(p=0.046)。
  • 两组围手术期并发症、住院时间和6个月健康相关生活质量基本相当。
  • 肿瘤学与功能结局将在更长随访中评估,以观察两组间潜在差异。

核心结论

  • 该前瞻性随机试验观察到RARC组和ORC组围手术期总体输血率分别为22%和41%,证实RARC联合体内尿流改道具有显著获益。
  • 围手术期并发症、住院时间和6个月健康相关生活质量两组基本相当。
  • 肿瘤学与功能结局将在更长随访中评估,以观察两组间潜在差异。

研究设计与样本

  • 单中心随机对照试验,纳入116例连续患者(RARC 58例,ORC 58例)。
  • 入组条件为经尿道膀胱肿瘤电切诊断为cT2-4、cN0、cM0或复发高级别非肌层浸润性膀胱癌,且无机器人手术麻醉禁忌证。
  • 采用基于体重指数、美国麻醉医师协会评分、基线血红蛋白、计划尿流改道方式、新辅助化疗和cT分期的协变量自适应随机化流程。
  • 主要终点为证明RARC联合体内尿流改道在输血率降低50%方面的优效性。

主要发现

  • 围手术期总体输血率RARC组22% vs ORC组41%(p=0.046),RARC组显著低于ORC组。
  • 围手术期并发症、住院时间和6个月健康相关生活质量两组基本相当。

局限性

  • 肿瘤学与功能结局将在更长随访中评估,以观察两组间潜在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radical cystectomy (RC) with urinary diversion (UD) is still considered a complex surgery associated with significant morbidity. Open RC (ORC) remains the reference option of treatment, even if adoption of robot-assisted RC (RARC) is rapidly increasing. To date, all the available randomized controlled trials were characterized by an extracorporeal approach in performing UD, undermining potential benefits of a totally minimally invasive procedure. In this study, we aimed to report perioperative and 6-month outcomes from the first RCT comparing ORC and RARC with totally intracorporeal UD. MATERIALS AND METHODS: Patients were eligible for randomization if they had a diagnostic transurethral resection of bladder tumor with cT2-4, cN0, cM0 or recurrent high-grade nonmuscle-invasive bladder cancer and no anesthesiological contraindications to robotic surgery. Patients were enrolled with a covariate adaptive randomization process based on the following variables: body mass index, American Society of Anesthesiologists® score, baseline hemoglobin, planned UD, neoadjuvant chemotherapy and cT stage. The primary end point was to demonstrate the superiority of RARC with intracorporeal UD in terms of a 50% transfusion rate reduction. RESULTS: Overall, 116 consecutive patients (58 RARC, 58 ORC) were enrolled. Among primary endpoint, overall perioperative transfusion rates were significantly lower in the RARC cohort (RARC: 22% vs ORC: 41%; p=0.046). CONCLUSIONS: This prospective randomized trial observed 22% and 41% overall perioperative transfusion rates in patients treated by RARC and ORC, respectively, confirming a significant benefit in favor of RARC with intracorporeal UD. However, perioperative complications, hospital stay and 6-month health-related quality of life were largely comparable between groups. Oncologic and functional outcomes will be assessed at longer followup to observe potential differences between arms.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Mastroianni R, Ferriero M, Tuderti G, et al. Open Radical Cystectomy versus Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Early Outcomes of a Single-Center Randomized Controlled Trial. J Urol. 2022. PMID: 34986007. doi:10.1097/JU.0000000000002422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。